Evidence map›Paper›PMID 38811964›Full record

ArticleJournal of nanobiotechnology2024

A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune.

Zhenzhen Jiang, Guangqing Cai, Haiting Liu, Leping Liu, Rong Huang, Xinmin Nie, Rong Gui, Jian Li, Jinqi Ma, Ke Cao and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Biomimetic Cell Membrane-Coated MOFs System for Targeted Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  5. Article
  6. Review
  7. Progress and prospects of metal-based immunotherapy in breast cancer.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhenzhen JiangDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Guangqing CaiDepartment of Orthopedics, Changsha Hospital of Traditional Chinese Medicine (Changsha Eighth Hospital), Changsha, Hunan, 410013, P. R. China.
Haiting LiuDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Leping LiuDepartment of Pediatrics, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Rong HuangDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Xinmin NieDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Rong GuiDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Jian LiDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Jinqi MaDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China.
Ke CaoDepartment of Oncology, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China. CSUcaoke@163.com.
Yanwei LuoDepartment of Blood Transfusion, The Third Xiangya Hospital, Central South University, Changsha, Hunan, 410013, China. royalway@csu.edu.cn.

Funding

Clinical Medical Technology Innovation Guide Project of Hunan Province 2021SK53715the National Natural Science Foundation of China Grant Nos.82172832Wisdom Accumulation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University YX202108
6 · The paper itself

Abstract

backgroundCombination therapy involving immune checkpoint blockade (ICB) and other drugs is a potential strategy for converting immune-cold tumors into immune-hot tumors to benefit from immunotherapy. To achieve drug synergy, we developed a homologous cancer cell membrane vesicle (CM)-coated metal-organic framework (MOF) nanodelivery platform for the codelivery of a TLR7/8 agonist with an epigenetic inhibitor.

methodsA novel biomimetic codelivery system (MCM@UN) was constructed by MOF nanoparticles UiO-66 loading with a bromodomain-containing protein 4 (BRD4) inhibitor and then coated with the membrane vesicles of homologous cancer cells that embedding the 18 C lipid tail of 3M-052 (M). The antitumor immune ability and tumor suppressive effect of MCM@UN were evaluated in a mouse model of triple-negative breast cancer (TNBC) and in vitro. The tumor immune microenvironment was analyzed by multicolor immunofluorescence staining.

resultsIn vitro and in vivo data showed that MCM@UN specifically targeted to TNBC cells and was superior to the free drug in terms of tumor growth inhibition and antitumor immune activity. In terms of mechanism, MCM@UN blocked BRD4 and PD-L1 to prompt dying tumor cells to disintegrate and expose tumor antigens. The disintegrated tumor cells released damage-associated molecular patterns (DAMPs), recruited dendritic cells (DCs) to efficiently activate CD8

conclusionMCM@UN specifically targeted to TNBC cells and remodeled tumor immune microenvironment to inhibit malignant behaviors of TNBC.

Indexed as

Toll-Like Receptor 7Toll-Like Receptor 8Triple Negative Breast NeoplasmsTumor MicroenvironmentAnimalsBromodomain Containing ProteinsCell Cycle ProteinsCell Line, TumorEpigenesis, GeneticFemaleHumansImmunotherapyMiceMice, Inbred BALB CNanoparticlesTranscription FactorsBRD4 protein, humanBromodomain Containing ProteinsCell Cycle ProteinsTLR7 protein, humanTLR8 protein, humanToll-Like Receptor 7Toll-Like Receptor 8Transcription FactorsBET inhibitorBiomimetic codelivery systemImmunogenic cell deathMetal-organic frameworkTriple-negative breast cancer (TNBC)Tumor immune microenvironment

Identifiers

PMID38811964
PMCPMC11134718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.